Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

NCT00316264 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections
Chronic Lung Disease and <= 24 Months of Age or
Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Interventions

BIOLOGICAL: Motavizumab, palivizumab
BIOLOGICAL: Palivizumab, motavizumab
BIOLOGICAL: Motavizumab

Sponsor

MedImmune LLC